Related Experiment Video

Updated: Nov 16, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Maya N White1, Zofia Piotrowska2, Kevin Stirling3

  • 1Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.

Clinical Lung Cancer
|February 21, 2021
PubMed
Abstract

Insights

Combining osimertinib with chemotherapy in advanced non-small cell lung cancer (NSCLC) showed promising central nervous system (CNS) control and manageable safety. This combination therapy demonstrated favorable duration on treatment and overall survival in heavily pre-treated patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy in non-small cell lung cancer (NSCLC) with EGFR mutations.
  • Limited data exists on the combination of osimertinib with chemotherapy in advanced NSCLC.
  • Understanding the efficacy and safety of this combination is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining osimertinib with chemotherapy in advanced EGFR-mutated NSCLC.
  • To assess outcomes including duration on treatment (DOT), overall survival (OS), and central nervous system (CNS) control.
  • To analyze safety profiles of concurrent osimertinib and chemotherapy regimens.

Main Methods:

  • Retrospective study at three institutions involving patients with advanced EGFR-mutated NSCLC.
  • Inclusion criteria: concurrent osimertinib and chemotherapy in the third-line or beyond.
  • Data collection via chart review, assessing efficacy (DOT, OS, CNS outcomes) and safety.

Main Results:

  • 44 patients met inclusion criteria; 28 received osimertinib plus platinum doublet, 29 received osimertinib plus single-agent chemotherapy.
  • Median DOT was 6.1 months with platinum doublet and 2.6 months with single-agent chemotherapy.
  • Median OS was 10.4 months; 84% had CNS metastases at baseline, with 24% experiencing CNS progression.

Conclusions:

  • Combination of osimertinib plus chemotherapy appears safe in advanced NSCLC patients with prior treatment progression.
  • Favorable CNS disease control was observed in this cohort.
  • DOT and survival outcomes were comparable to historical chemotherapy controls.
Keywords:
Brain metastasesChemotherapyCombination therapyEGFREGFR tyrosine kinase inhibitorOsimertinibTargeted therapy

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
856